Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2025 13:30 ET | Source: F. Hoffmann-La Roche Ltd

Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology

Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer,...
February 12, 2025 11:45 ET | Source: F. Hoffmann-La Roche Ltd

FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and...
February 07, 2025 03:45 ET | Source: F. Hoffmann-La Roche Ltd

New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis

Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard...
February 04, 2025 11:45 ET | Source: F. Hoffmann-La Roche Ltd

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)With as few as two treatments per year, Susvimo...
January 31, 2025 11:45 ET | Source: F. Hoffmann-La Roche Ltd

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be...
January 30, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum

Basel, 30. Januar 2025 Konzernverkäufe stiegen um 7%1 zu konstanten Wechselkursen (CER; 3% in CHF) dank hoher Nachfrage sowohl nach Medikamenten als auch nach Diagnostika.Ohne COVID-19-Produkte...
January 30, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%....
January 29, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Change to the Roche Enlarged Corporate Executive Committee

Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas...
January 28, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

Updated overall survival (OS) results - a key secondary endpoint - reinforce the significant benefit of the ItovebiTM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positive,...
January 27, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to Rise (TTR) and 10-meter walk/run (10MWR), results were statistically significant and clinically meaningful two...